The size of the In-vitro Toxicology Testing Market in North America is expected to reach USD 13196.68 Million by 2028 from USD 6954.01 Million in 2023, growing at a CAGR of 13.67% from 2023 to 2028. Rise in the number of R & D procedures, which require in vitro testing, restrictions on animal testing, and an increase in awareness about environmental concerns are the major factors driving the North America In-Vitro toxicology testing market.
In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is essential in drug discovery as it identifies the poisonous effects of a new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Favorable regulatory authorities for toxicology testing using the in-vitro tests, growing technological advancements in toxicity testing models, increasing research & development expenditure towards cell culture are primarily fuelling the market growth. The existence of stringent regulations related to animal utilization for toxicity testing and growing demand for in-vitro tests to drive the growth of the in-vitro toxicology testing market in North America. However, the requirement of extensive validation procedures for new in-vitro methods and the presence of stringent social & scientific laws about toxicology testing studies are some of the factors that restrain the growth of the in-vitro toxicology testing market North America.
This research report segmented and sub-segmented into the following categories:
Based on geographical areas, the U.S. is estimated to account for a more significant share of the North America in-vitro toxicology testing market in 2019. In contrast, Canada is expected to grow at a higher CAGR during the forecast period.
In 2019, the United States accounted for the most significant market share in North America. Developments in the genetics and genetic screening approaches and the emergence of new approaches of 3D cell culture are majorly helping the U.S. market.
Moreover, supportive government authority has led to the fast development of new, cost-effective testing for establishing drug, device, chemical, and cosmetic safety in the United States. The ideal increase in investment in instruments and the ongoing expansion of laboratory capabilities, across the region, currently, enable the consumer to establish toxicological profiles of medical devices, biopharmaceuticals, cosmetics, and chemicals. These investments contain a widen the existing cell/tissue culture power, and mass spectrometry facilities, flow cytometry, other than the launching of high throughput screening, multiplexing technologies, and automation for biomarker examination.
Most promising companies operating in the North American In-Vitro Toxicology Testing Market profiled in the report are Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.) and Cyprotex (U.K.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org